Sam Williams

Sam has over 20 years’ experience in the biotechnology industry, both as a top-ranked equity analyst in the City of London and, subsequently, as a chief executive and investor.

Sam is Executive Chairman of Istesso Limited, a London-based drug-discovery company, and Head of Life Sciences at IP Group where he serves as Chairman of portfolio companies Diurnal Group plc, Iksuda Ltd and Microbiotica Ltd, and as a non-executive director on the boards of Pulmocide Ltd, IESO Ltd and Kuur Therapeutics. Sam has PhD in molecular biology from Cambridge and a degree in biology from Oxford.